News
EYPT
6.71
+3.15%
0.21
Weekly Report: what happened at EYPT last week (0414-0418)?
Weekly Report · 2d ago
EYEPOINT PHARMACEUTICALS REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 04/16 11:00
Weekly Report: what happened at EYPT last week (0407-0411)?
Weekly Report · 04/14 10:51
Weekly Report: what happened at EYPT last week (0331-0404)?
Weekly Report · 04/07 10:50
Weekly Report: what happened at EYPT last week (0324-0328)?
Weekly Report · 03/31 11:00
Weekly Report: what happened at EYPT last week (0317-0321)?
Weekly Report · 03/24 10:50
Weekly Report: what happened at EYPT last week (0310-0314)?
Weekly Report · 03/17 10:59
Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 03/14 12:12
Analysts Offer Insights on Healthcare Companies: OnKure Therapeutics (OKUR) and EyePoint Pharmaceuticals (EYPT)
TipRanks · 03/10 23:50
Weekly Report: what happened at EYPT last week (0303-0307)?
Weekly Report · 03/10 11:00
JonesTrading Remains a Buy on EyePoint Pharmaceuticals (EYPT)
TipRanks · 03/07 21:36
EyePoint Pharma’s Earnings Call: Clinical Progress Amid Financial Challenges
TipRanks · 03/07 00:10
EyePoint Pharmaceuticals Price Target Maintained With a $33.00/Share by Chardan Capital
Dow Jones · 03/06 22:07
EyePoint Pharmaceuticals Is Maintained at Buy by Chardan Capital
Dow Jones · 03/06 22:07
Demystifying EyePoint Pharmaceuticals: Insights From 4 Analyst Reviews
Benzinga · 03/06 22:01
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $33 Price Target
Benzinga · 03/06 21:58
Guggenheim Remains a Buy on EyePoint Pharmaceuticals (EYPT)
TipRanks · 03/06 14:07
EyePoint Pharmaceuticals Price Target Maintained With a $22.00/Share by HC Wainwright & Co.
Dow Jones · 03/06 12:02
HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $22 Price Target
Benzinga · 03/06 11:52
EyePoint Pharmaceuticals: Promising Clinical Progress and Strong Financial Position Justify Buy Rating
TipRanks · 03/06 11:38
More
Webull provides a variety of real-time EYPT stock news. You can receive the latest news about Eyepoint Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About EYPT
More
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.